Fluorinated anthracyclines: Synthesis and biological activity Ken C. TonkinRobert T. C. BrownleeDon R. Phillips Preclinical Studies Pages: 1 - 6
Experimental antitumor activity of BMY-28175 a new fermentation derived antitumor agent John E. SchurigWilliam C. RoseDale A. Stringfellow Preclinical Studies Pages: 7 - 15
Discrepancy between cytotoxicity and DNA interstrand crosslinking of carboplatin and cisplatin in vivo Wilfried DeNeveFrederick ValerioteThomas Corbett Preclinical Studies Pages: 17 - 24
Pharmacokinetics of the antitumor antibiotic n-pentyl-sparsomycin in beagle dogs Zbigniew ZyliczD. J. Theo WagenerHarry C. J. Ottenheijm Preclinical Studies Pages: 25 - 32
Assessment of pulmonary and hematologic toxicities of liblomycin, a novel bleomycin analog Robert A. NewmanZahid H. SiddikIrwin H. Krakoff Preclinical Studies Pages: 33 - 41
Phase I study of oral menogaril administered on a once weekly schedule David J. StewartShailendra VermaRobert H. Earhart OriginalPaper Pages: 43 - 52
Phase I study of oral spirogermanium Jimmie HarveyMolly McFaddenPhilip S. Schein OriginalPaper Pages: 53 - 56
Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion Carol J. FabianRoy MolinaRonald Stephens OriginalPaper Pages: 57 - 63
High dose folinic acid/etoposide/5-fluorouracil in advanced gastric cancer — a phase II study in elderly patients or patients with cardiac risk H. WilkeP. PreusserH. -J. Schmoll OriginalPaper Pages: 65 - 70
Phase II study of CHIP chemotherapy in advanced adenocarcinomas of the upper gastrointestinal tract Alec S. GoldenbergDavid KelsenGordon Magill OriginalPaper Pages: 71 - 75
Phase II evaluation of mitoxantrone in advanced pancreatic carcinoma: A Southwest Oncology Group study Sarah A. TaylorThomas FlemingJohn H. Costanzi OriginalPaper Pages: 77 - 80
Phase II evaluation of esorubicin (4′ deoxydoxorubicin) in pancreatic adenocarcinoma: A Southwest Oncology Group study Clarence B. VaughnSydney E. SalmonThomas R. Fleming OriginalPaper Pages: 81 - 85
An evaluation of combination 5-fluorouracil and spirogermanium in the treatment of advanced colorectal carcinoma Mary L. McMasterF. Anthony GrecoJohn D. Hainsworth OriginalPaper Pages: 87 - 92
VM-26 in colorectal carcinoma: A Southwest Oncology Group study Noboru OishiThomas R. FlemingJohn S. Macdonald OriginalPaper Pages: 93 - 95
Phase II trial of 4′ deoxydoxorubicin (DXDX) for unresectable non-small cell bronchogenic carcinoma Christopher RoseThomas E. LadCarole M. Johnson OriginalPaper Pages: 97 - 99
Aclacinomycin A in the treatment of multiple myeloma: A Southwest Oncology Group study Chatchada KaranesJohn CrowleySydney Salmon OriginalPaper Pages: 101 - 104
Southwest Oncology Group study of mitoxantrone for treatment of patients with advanced adenoid cystic carcinoma of the head and neck Douglas E. MattoxDaniel D. Von HoffStanley P. Balcerzak OriginalPaper Pages: 105 - 107
A phase II study of mitoxantrone in advanced squamous cell cancer of the head and neck H. WheelerR. L. WoodsJ. Levi OriginalPaper Pages: 109 - 111
Phase II trial of 6-diazo-5-oxo-L-norleucine versus aclacinomycin-A in advanced sarcomas and mesotheliomas Robert H. EarhartDavid J. AmatoThomas J. Smith OriginalPaper Pages: 113 - 119
Phase II study of trimetrexate in malignant melanoma: A National Cancer Institute of Canada Clinical Trials Group Study Neill A. IscoeElizabeth A. EisenhauerAudley J. Bodurtha OriginalPaper Pages: 121 - 123
A phase II trial of peg-L-asparaginase in the treatment of non-hodgkins lymphoma Hyman B. MussNancy SpellAnita Franklin OriginalPaper Pages: 125 - 130
